Investment Rating - The report assigns a strategic significance to the acquisition of approximately 29.06% of PUMA SE, with a target price of €35 per share, representing a 61.6% premium over the closing price prior to the announcement [2]. Core Insights - The acquisition is valued at approximately €1.505 billion (around 12.278 billion RMB), positioning the reporting company as PUMA's largest single shareholder [2]. - The company views PUMA's long-term brand value and market position, particularly in football and running, as underappreciated in its current stock price, providing a favorable long-term investment opportunity [2]. - The revenue contribution of PUMA from the Chinese market is only about 7%, indicating significant growth potential, with plans to leverage the company's successful "brand + retail" model to enhance PUMA's performance in China [2]. - The acquisition is a critical step in the company's "single focus, multi-brand, globalization" strategy, enhancing its global presence through PUMA's strong influence in Europe, North America, and Africa [2]. Financial Projections - The company has adjusted its profit forecasts, expecting net profits for the fiscal years 2025-2027 to be 13.197 billion, 14.129 billion, and 15.417 billion RMB, respectively, with corresponding P/E ratios of 14.65X, 13.68X, and 12.54X [3]. - Revenue projections for the fiscal years 2025-2028 are estimated at 70.826 billion, 78.263 billion, 85.306 billion, and 92.557 billion HKD, with year-on-year growth rates of 14%, 11%, 9%, and 9% [4]. - The company's diluted EPS is projected to be 4.72, 5.05, and 5.51 HKD for the fiscal years 2025, 2026, and 2027, respectively [4].

证券研究报告·海外公司研究简报·专业零售(HS) 周大福（01929.HK） 黄金珠宝百年龙头品牌，战略转型+产品升级 开启成长新篇章 买入（首次） | [Table_EPS] 盈利预测与估值 | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万港元） | 108,713 | 89,656 | 94,265 | 99,234 | 105,213 | | 同比(%) | 14.82 | (17.53) | 5.14 | 5.27 | 6.03 | | 归母净利润（百万港元） | 6,499 | 5,916 | 8,873 | 9,958 | 11,058 | | 同比(%) | 20.71 | (8.98) | 50.00 | 12.23 | 11.04 | | EPS-最新摊薄（港元/股） | 0.66 | 0.60 | 0.90 | 1.01 | 1.12 | | P/E（现价&最新摊薄） | 20.43 | 22.44 | 14.96 | 13.33 | 12 ...

证券研究报告·海外公司研究简报·专业零售(HS) [Table_Tag] [Table_Summary] 投资要点 [Table_Summary] 投资要点 2026 年 01 月 29 日 证券分析师 吴劲草 执业证书：S0600520090006 wujc@dwzq.com.cn 证券分析师 郗越 执业证书：S0600524080008 周大福（01929.HK） 黄金珠宝百年龙头品牌，战略转型+产品升级 开启成长新篇章 买入（首次） | [Table_EPS] 盈利预测与估值 | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万港元） | 108,713 | 89,656 | 94,265 | 99,234 | 105,213 | | 同比(%) | 14.82 | (17.53) | 5.14 | 5.27 | 6.03 | | 归母净利润（百万港元） | 6,499 | 5,916 | 8,873 | 9,958 | 11,058 | | 同比(%) | ...

证券研究报告·海外公司研究简报·专业零售(HS) 周大福（01929.HK） 黄金珠宝百年龙头品牌，战略转型+产品升级 开启成长新篇章 买入（首次） [Table_Tag] [Table_Summary] 投资要点 [Table_Summary] 投资要点 证券分析师 郗越 执业证书：S0600524080008 xiy@dwzq.com.cn 股价走势 -2% 13% 28% 43% 58% 73% 88% 103% 118% 133% 2025/2/3 2025/6/2 2025/9/29 2026/1/26 周大福 恒生指数 2026 年 01 月 29 日 证券分析师 吴劲草 执业证书：S0600520090006 wujc@dwzq.com.cn | [Table_EPS] 盈利预测与估值 | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万港元） | 108,713 | 89,656 | 94,265 | 99,234 | 105,213 | | 同比 ...

公司研究 FY26Q2 业绩超预期增长，全年收入指引上调彰显信心 ——新东方-S（9901.HK）FY26Q2 业绩点评 买入（上调） 当前价：44.70 港元 2026 年 1 月 29 日 作者 分析师：陈彦彤 执业证书编号：S0930518070002 021-52523689 chenyt@ebscn.com 分析师：汪航宇 执业证书编号：S0930523070002 021-52523174 wanghangyu@ebscn.com 分析师：聂博雅 执业证书编号：S0930522030003 021-52523808 nieboya@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 15.80 | | 总市值(亿港元)： | 706.39 | | 一年最低/最高(港元)： | 30.85/47.31 | | 近 3 月换手率： | 14.06% | 股价相对走势 -20% -10% 0% 10% 20% 30% 40% 50% 25/1 25/2 25/3 25/4 25/5 25/6 25/7 25/8 25/9 25/10 25/11 25/12 26 ...

[Table_Page] 公告点评|公用事业Ⅱ 证券研究报告 [Table_Title] 【广发 环 保 & 海 外 】 粤 海 投 资 （00270.HK） 预告 25 年归母净利润同比增长 43%，股息价值突出 [Table_Summary] 核心观点： 备注：除非特别说明，否则报告货币为港元 | 盈利预测： | | --- | | [Table_ 单位Finance] :港元百万元 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 主营收入 | 20,322 | 18,505 | 18,528 | 18,667 | 18,769 | | 增长率（ % ） | -12.4% | -8.9% | 0.1% | 0.8% | 0.5% | | EBITDA | 9,920 | 9,909 | 10,272 | 10,309 | 10,326 | | 归母净利润 | 4,370 | 4,297 | 4,493 | 4,638 | 4,770 | | 增长率（ % ） | -8.3% | -1.7% ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][88]. Core Insights - The leisure food and beverage industry in China is experiencing rapid expansion, with a projected GMV growth from 2.9 trillion yuan to 3.7 trillion yuan from 2019 to 2024, reflecting a CAGR of 5.5% [3][10]. - The company, "鸣鸣很忙," is positioned as the leading group in the mass retail sector, with revenue expected to exceed 39.3 billion yuan by 2024, showcasing strong growth potential [3][29]. - The company is exploring international markets, particularly in Southeast Asia, where the snack market is diversifying and showing significant growth [3][64]. Summary by Sections Industry Expansion - The leisure food and beverage sector is projected to grow significantly, with the down-market segment being a key driver, increasing from 1.7 trillion yuan to 2.3 trillion yuan (CAGR 6.5%) [3][10]. - The market is witnessing a shift towards specialized retail channels, with the growth of specialty stores and e-commerce, reflecting changing consumer preferences [10][11]. Company Overview - "鸣鸣很忙" is consolidating its position as the first mass retail group through brand mergers, with a revenue forecast of 39.3 billion yuan by 2024 [3][29]. - The company has achieved a significant increase in store count, reaching 19,517 stores by the third quarter of 2025, with a focus on lower-tier cities [3][41]. Financial Performance - Revenue is expected to grow from 63.06 billion yuan in 2025 to 89.93 billion yuan in 2027, with adjusted net profit projected to rise from 2.52 billion yuan to 4.68 billion yuan during the same period [3][88]. - The company is expected to achieve a stable gross margin of 9.73% by 2025, driven by operational efficiencies and a digital marketing strategy [3][29]. International Expansion - The Southeast Asian snack market is projected to reach 12.3 billion USD by 2024, with a notable demand for health-oriented snacks [3][64]. - The company is leveraging its supply chain advantages to penetrate markets in Thailand, Indonesia, and Vietnam, where local consumer preferences are evolving [3][67].

Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, indicating an expected return exceeding the market benchmark over the next 12-18 months [2][19]. Core Insights - Zai Lab is projected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product, efgartigimod, is expected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management emphasizes a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25-FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss estimates for the same period are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503 for atopic dermatitis and ZL-6201 for various solid tumors, are anticipated to contribute to long-term global value [6][9][21].

上 市 公 司 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2026 年 01 月 28 日 | | --- | --- | | 收盘价（港币） | 22.10 | | 恒生中国企业指数 | 9512.24 | | 52 周最高/最低（港币） | 53.70/10.12 | | H 股市值（亿港币） | 232.89 | | 流通 H 股（百万股） | 1,053.81 | | 汇率（港币/人民币） | 0.8943 | 一年内股价与基准指数对比走势： 2026 年 01 月 29 日 东方甄选 (01797) ——产品组合优化，经营效益大幅提升 公 司 研 究 / 公 司 点 评 社会服务 -37% 63% 163% 263% 01/28 02/28 03/31 04/30 05/31 06/30 07/31 08/31 09/30 10/31 11/30 12/31 HSCEI 东方甄选 资料来源：Bloomberg 相关研究 - 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 联系人 投资要点： 东方甄选 1HFY26（2025 年 ...

公司深度研究 | 禾赛-W 全球激光雷达龙头，赋能高阶智驾&机器人 禾赛（2525.HK）首次覆盖报告 【核心结论】我们预计公司 2025-2027 年的总收入为 31 亿/48 亿/61 亿元， 归母净利润为 3.7 亿/6.9 亿/10.9 亿元。公司作为全球激光雷达龙头，有望在 高阶智能驾驶&机器人等领域快速拓展。首次覆盖，给予"买入"评级。 报告亮点：市场认为，激光雷达空间有限，我们认为：仅车端市场，我们预 计 10 万+价格带车型有望快速搭载激光雷达，在自动驾驶升级过程中，激光 雷达单车搭载量（补盲）和 ASP（高性能化）将有所提升。考虑到出海、机 器人、无人物流、无人仓储等多种场景，激光雷达空间广阔。 主要逻辑#1：公司创始人分工明确，优势互补，战略领先。禾赛科技的三位 创始人分别是李一帆、孙恺和向少卿，李一帆负责公司的整体战略规划和运 营管理，孙恺负责公司激光雷达产品的核心技术研发，向少卿专注于激光雷 达的系统集成和软件算法开发。我们认为，公司在早期切入市场的选择（L4 级市场）、从早期就坚持芯片化激光雷达和转镜技术路线的开发，以及对专 有制造的坚持，都体现了公司前瞻的战略眼光和优秀的管理团队素 ...